Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of SAR445399, a drug administered by injection, in adults with moderate to severe hidradenitis suppurativa. This multinational, randomized, double-blind, placebo-controlled Phase 2 study aims to compare two different doses of SAR445399 with a placebo to find the best dose for treating this condition. Participants will be randomly assigned to receive one of two SAR445399 dose regimens or a matching placebo. The treatment period lasts 32 weeks, including a 16-week initial double-blind phase followed by a 16-week treatment-blinded extension period. The total study duration for each participant is up to 46 weeks, with a total of 16 study visits scheduled throughout this time. During the study, participants will be monitored through various assessments including clinical response measures such as Hidradenitis Suppurativa Clinical Response HiSCR levels, severity scoring, skin pain ratings, quality of life questionnaires, laboratory tests, vital signs, and electrocardiograms. Researchers will also track drug concentrations and immune responses. Safety will be closely monitored throughout the study and extension period to evaluate any adverse events or significant changes in health.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of frexalimab compared to tacrolimus in adults undergoing their first kidney transplant who have a low to moderate risk of organ rejection. This open-label, randomized study will span up to approximately 5 years, aiming to understand how these treatments perform in kidney transplant recipients. The study is sponsored by Sanofi and involves adults aged 18 to 70 years. Participants will receive either frexalimab or tacrolimus as part of their immunosuppressive therapy. The initial dose of frexalimab is given intravenously, followed by subcutaneous doses administered using an on-body delivery system. Tacrolimus is given orally as capsules. The study includes about 38 visits over the treatment period, which may extend up to 5 years. During the study, participants will be regularly monitored through various assessments including kidney function tests, measurement of rejection episodes, antibody levels, and side effects related to immunosuppressive therapy. Researchers will track outcomes such as graft survival, participant survival, kidney filtration rates, and cardiovascular events over time. Safety and drug levels will also be closely observed throughout the study duration.
Actively Recruiting
Researchers are evaluating SAR446523, an anti-GPRC5D ADCC-enhanced monoclonal antibody, in adults with relapsed or refractory multiple myeloma who have received multiple prior treatments. This first-in-human, open-label Phase 1 trial aims to assess the safety, antitumor activity, and pharmacokinetics of SAR446523. The study is sponsored by Sanofi and will continue until the last participants last visit, allowing therapy continuation until disease progression, unacceptable side effects, or discontinuation requests. The trial has two parts Part A involves dose escalation to find the maximum tolerated and recommended dose range at several dose levels of SAR446523 given by subcutaneous injection. Part B is a dose optimization phase where participants are randomly assigned to one of two dose regimens determined from Part A data to establish the recommended phase 2 dose. Participants receive SAR446523 subcutaneously in both parts. Participants will undergo safety evaluations, laboratory tests, and assessments for adverse events during treatment lasting up to approximately five years. Researchers will measure dose-limiting toxicities, overall response rates, and other efficacy outcomes such as progression-free survival and duration of response over 24 months after the last participant is enrolled. The study also monitors pharmacokinetics, immunogenicity, and quality of life impact throughout the treatment and follow-up period.